AI-assisted approach identifies IRS4 as a promising drug target in multiple solid tumors

MedicalXpress | أبر 30, 2026

Leveraging AI capabilities combined with genetic data led St. Jude Children's Research Hospital investigators to predict new cancer drug targets that carry a limited risk of side effects. For their study, published in Science Advances, St. Jude Children's Research Hospital scientists used a mix of genetic cancer dependency data, artificial intelligence (AI), and naturally occurring mutations to prioritize safer cancer drug targets.